Name:
Publisher version
View Source
Access full-text PDFOpen Access
View Source
Check access options
Check access options
Average rating
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Star rating
Your vote was cast
Thank you for your feedback
Thank you for your feedback
Issue Date
2019-12-02
Metadata
Show full item recordAbstract
In recent years, extracellular vesicles (EVs) and outer membrane vesicles (OMVs) have become an extensive and diverse field of research. They hold potential as diagnostic markers, therapeutics and for fundamental biological understanding. Despite ongoing studies, numerous information regarding function, content and stability of EVs remains unclear. If EVs and OMVs ought to be used as therapeutics and in clinical environments, their stability is one of the most important factors to be considered. Especially for formulation development, EVs and OMVs need to be stable at higher temperatures. To the best of our knowledge, very little work has been published regarding heat stability of neither EVs nor OMVs. In the present study, we investigated B lymphoblastoid cell-derived EVs and OMVs derived from myxobacterial species Sorangiineae as model vesicles. We exposed the vesicles to 37 °C, 50 °C, 70 °C and 100 °C for 1 h, 6 h and 24 h, and also autoclaved them. Interestingly, physico-chemical analyses such as size, particle concentration and protein concentration showed minor alterations, particularly at 37 °C. Flow cytometry analysis emphasised these results suggesting that after heat impact, EVs and OMVs were still able to be taken up by macrophage-like dTHP-1 cells. These data indicate that both mammalian and bacterial vesicles show intrinsic stability at physiological temperature. Our findings are important to consider for vesicle formulation and for advanced bioengineering approaches.Citation
Eur J Pharm Biopharm. 2019 Dec 2. pii: S0939-6411(19)31309-8. doi: 10.1016/j.ejpb.2019.11.010.Affiliation
HIPS, Helmholtz-Institut für Pharmazeutische Forschung Saarland, Universitätscampus E8.1 66123 Saarbrücken, Germany.Publisher
ElsevierPubMed ID
31805356Type
ArticleLanguage
enISSN
1873-3441ae974a485f413a2113503eed53cd6c53
10.1016/j.ejpb.2019.11.010
Scopus Count
The following license files are associated with this item:
- Creative Commons
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-ShareAlike 4.0 International
Related articles
- Myxobacteria-Derived Outer Membrane Vesicles: Potential Applicability Against Intracellular Infections.
- Authors: Goes A, Lapuhs P, Kuhn T, Schulz E, Richter R, Panter F, Dahlem C, Koch M, Garcia R, Kiemer AK, Müller R, Fuhrmann G
- Issue date: 2020 Jan 12
- Biocompatible bacteria-derived vesicles show inherent antimicrobial activity.
- Authors: Schulz E, Goes A, Garcia R, Panter F, Koch M, Müller R, Fuhrmann K, Fuhrmann G
- Issue date: 2018 Nov 28
- A post-insertion strategy for surface functionalization of bacterial and mammalian cell-derived extracellular vesicles.
- Authors: Jiang L, Luirink J, Kooijmans SAA, van Kessel KPM, Jong W, van Essen M, Seinen CW, de Maat S, de Jong OG, Gitz-François JFF, Hennink WE, Vader P, Schiffelers RM
- Issue date: 2021 Apr
- Mesenchymal stromal cell-derived nanovesicles ameliorate bacterial outer membrane vesicle-induced sepsis via IL-10.
- Authors: Park KS, Svennerholm K, Shelke GV, Bandeira E, Lässer C, Jang SC, Chandode R, Gribonika I, Lötvall J
- Issue date: 2019 Aug 1
- Outer membrane vesicles for vaccination and targeted drug delivery.
- Authors: Wang S, Gao J, Wang Z
- Issue date: 2019 Mar